Outpatient Surgery Magazine, providing current information on Surgical Services, Surgical Facility Administration, Outpatient Surgery News and Trends, OR Excellence and more.
Issue link: http://outpatientsurgery.uberflip.com/i/822813
3. Are they approachable and accountable? Running a surgical facility is like cultivating a garden. There's always something to tend to. Your anesthesia group needs to be reachable at all times — not only by the administrator, but by surgeons and patients as well. Depending on the concern, you also need to know you can reach the right mem- bers of the group quickly. If you'd prefer to meet in person, they should accom- modate that as well. 4. Are they experi- enced in the types of cases your facility specializes in? Make certain they've been providing anes- thesia on a regular basis for the types of cases your facility hosts, especially if you're a high-volume center with a special- ty like vascular, ENT, urology, spine or orthopedics. You 5 4 • O U T PA T I E N T S U R G E R Y M A G A Z I N E • M a y 2 0 1 7 Important Safety Information The use of The use of Revonto in the management of malignant hyperthermia crisis is not a substitute for previously known supportive measures. These measures must be individualized, but it will usually be necessary to discontinue the suspect triggering agents, attend to increased oxygen requirements, manage the metabolic acidosis, institute cooling when necessary, monitor urinary output, and monitor for electrolyte imbalance. Patients who receive i.v. dantrolene sodium preoperatively should have vital signs monitored. If patients judged malignant hype If patients judged malignant hyperthermia susceptible are administered dantrolene sodium preoperatively, anesthetic preparation must still follow a standard malignant hyperthermia susceptible regimen, including the avoidance of known triggering agents. Monitoring for early clinical and metabolic signs of malignant hyperthermia is indicated because attenuation of malignant hyperthermia, rather than prevention, is possible. Despite initial satisfacto Despite initial satisfactory response to i.v. dantrolene there have been reports of fatality, which involve patients who could not be weaned from dantrolene after initial treatment. The administration of i.v. dantrolene is associated with loss of grip strength and weakness in the legs, as well as drowsiness and dizziness. There have been reports of thrombophlebitis following administration of intravenous dantrolene. Tissue necrosis secondary to extravasation has been reported. Injection site reactions (pain, erythema, swelling), commonly due to extravasation, have been reported. Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therap liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy. To report SUSPECTED ADVERSE REACTIONS contact US WorldMeds at 1-888-900-8796 or MEDWATCH at 1-800-FDA-1088 (1-800-332-1088) or http://www.FDA.gov/medwatch/. To see the full prescribing information visit www.revonto.com. © 2017. US WorldMeds, LLC. Revonto is a registered trademark of US WorldMeds, LLC. REV-P91-0217 ® 36 month shelf life* Ready to administer in 20 seconds † Are You Prepared for a CRISIS? Visit www.revonto.com or call (877) 411-USWM (8796) to learn more and to see the full Prescribing Information. *from the date of manufacture † or until solution is clear